Last reviewed · How we verify

TYSABRI and AVONEX — Competitive Intelligence Brief

TYSABRI and AVONEX (TYSABRI and AVONEX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (TYSABRI); Interferon (AVONEX). Area: Immunology / Neurology.

marketed Monoclonal antibody (TYSABRI); Interferon (AVONEX) α4-integrin (TYSABRI); Interferon-beta receptor (AVONEX) Immunology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

TYSABRI and AVONEX (TYSABRI and AVONEX) — Biogen. TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TYSABRI and AVONEX TARGET TYSABRI and AVONEX Biogen marketed Monoclonal antibody (TYSABRI); Interferon (AVONEX) α4-integrin (TYSABRI); Interferon-beta receptor (AVONEX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (TYSABRI); Interferon (AVONEX) class)

  1. Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TYSABRI and AVONEX — Competitive Intelligence Brief. https://druglandscape.com/ci/tysabri-and-avonex. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: